Tony D’Amore, Vice-President, Global Product Research & Development Sanofi Pasteur
Dr. Markus Haindl, Director Development Analytics Roche Diagnostics GmbH, Germany
Bonnie K. Shum, Engineer II (Global Biologics MSAT) Genentech Inc., A member of the Roche...
Richard Hart, Associate Principal Scientist Ian Ashworth, Associate Principal Scientist A...
Sameer Talwar1, Benoit Igne2, Juan Aon3, Dave Stevenson3, Janice Fernandez3, Diana Ritz3, ...
Barbara Paldus, PhD, Vice President and General Manager, Finesse, a part of Thermo Fisher ...
Willem Kools, PhD., Head of Technology
As biopharmaceutical projects occupy an increasingly larger share of the development pipeline, drug makers are striving to implement strategies that bring affordable therapies to market quickly and cost effectively.
Over the past several years, the adoption of single-use technology has emerged as one important strategy for improving downstream and upstream processing while avoiding the downsides of traditional stainless-steel bioreactors…
John Amara, Ph.D. and Michael Dullen, Merck
Recent advancements in the productivity of upstream cell culture processes for the manufacture of therapeutic proteins, including monoclonal antibodies (mAbs), have resulted in greatly elevated cell densities and higher levels of process-related impurities. Current depth filters may demonstrate an insufficient filtration capacity for these applications and often comprise naturally-derived materials which require increased flushing to remove undesired organic and inorganic extractable components.
Ruud Hulspas, Ph.D., Founder Cellular Technologies Bioconsulting, LLC
Manufacturing of all cell-based drugs requires accurate characterization of living cells. Depending on the design of the quality system, cell product characterization takes place during checkpoints at multiple stages of the manufacturing process (figure 1)…
Kirsten Strahlendorf, Senior Scientist in Research and Development at Sanofi Pasteur in Toronto
New vaccine process designs – and all the kinks that go with them – are typically hammered out in a small scale capacity, for example, prior to manufacturing for early phase human clinical trials. They are then upsized and further defined for industrial scale to supply the vast market…View All Featured Articles
Read All Headlines
DSF and FTIR as complementary methods for the identification and characterization of vaccine products
Presented by Marina Kirkitadze, Deputy Director, Head of Biophysics & Conformation Unit, Analytical R&D Biochemistry, Sanofi Pasteur and Rina Dukor, President, BioTools
18th September 2018
Presented by Sekhar Reddy, DSP Lead for Biosimilars at Biocon MSAT
25th January 2019
Presented by John Duguid
08th November 2018
View All Upcoming Webinars
Presented by Presented by Dr David Roesti, Novartis/USP and Erin Patton, Senior Product Specialist, Charles River
30th May 2018
Presented by Gert Moelgaard
15th February 2018
Presented by Dr. Ping Wang, Principal Scientist, Janssen R&D and Dr Nixdorf, SGS Group
05th June 2018
View All Past Webinars
View All Companies
Need assurance of SU connector traceability and quality?
View All Videos
Read All Technical Papers
View All Products